NDASUBCUTANEOUSPOWDERPriority Review
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
18/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
ZYCUBO (copper histidinate) by Sentynl Therapeutics. Approved for menkes disease. First approved in 2026.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
Copper Histidinate Treatment for Menkes Disease
Menkes Disease
Why This Matters for Your Career
Worked on ZYCUBO at Sentynl Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.